Acupuncture in subjects with cold hands sensation: study protocol for a randomized controlled trial

Jung-Chul Seo1†, Hyun-jong Lee2†, Min-Ah Kwak3, Sung-Hoon Park1, ImHee Shin4, Woo-Sung Yun5 and Kihyuk Park5*

Abstract

Background: Cold hands sensation is a common disorder within the Korean population. Many Korean family physicians believe that it is a mild early manifestation of Raynaud’s phenomenon (RP), or may be related to RP. RP is characterized by reversible digital vasospasm provoked by cold temperatures and/or emotional stress, and doctors often prescribe medications that are used in treatment of RP for subjects with cold hands. However, this has not shown a clear benefit, and these medications can cause unwanted side effects. It is also reported that traditional Korean medicine, including acupuncture, is widely used to treat cold hands, although the current level of evidence for this approach is also poor and to date, there have been no published randomized controlled clinical trials (RCTs) evaluating the efficacy and safety of acupuncture for cold hands. We have therefore designed a pilot RCT to obtain information for the design of a further full-scale trial.

Methods/Design: The proposed study is a five-week pilot RCT. A total of 14 subjects will be recruited and randomly allocated to two groups: an acupuncture plus medication group (experimental group) and a medication-only group (control group). All subjects will take nifedipine (5 mg once daily) and beraprost (20 mg three times daily) for three weeks. The experimental group will receive additional treatment with three acupuncture sessions per week for three weeks (nine sessions total). The primary outcome will be measured using a visual analogue scale. Secondary outcomes will be measured by blood perfusion in laser Doppler perfusion imaging of the hands, frequency and duration of episodes of cold hands, and heart rate variability. Assessments will be made at baseline and at one, three, and five weeks thereafter.

Discussion: This study will provide an indication of the feasibility and a clinical foundation for a future large-scale trial.

Trial registration: This study was registered at Korean Clinical Research Information Service (CRIS) registry on 5 August 2013 with the registration number #KCT0000817.

Keywords: Acupuncture, Cold hands sensation, Laser Doppler perfusion image

Background

One of the normal physiological responses to cold temperatures or emotional stress is a reduction of the skin temperature to preserve body heat and maintain a normal body core temperature. Reactions characterized by excessive peripheral vasospasm may evoke clinical symptoms, and complaints of cold hands sensation are very common among the general population [1]. Cold hands sensation is defined as hands that become intolerably cold when exposed to normal temperature, in which most individuals feel no cold. There can be a confusion between cold hands sensation and Raynaud’s phenomenon (RP), as both have cold hands as a symptom. The signs of RP include cold and numb hands when exposed to cold temperatures, with subsequent pain and skin becoming blue in colour [2]. In a community-based survey of approximately 7,000 people, almost 12% responded that they had experienced unusual
sensitivity to cold temperatures in their fingertips or toes [3,4]. This may be due to a mild, early manifestation of Raynaud's phenomenon (RP) or may be related to RP [1,5], which is characterized by a reversible digital vasospasm provoked by cold temperatures and/or emotional stress [6]. A study by Choi et al. [7] found that in South Korea, 43% of patients with an abnormal cold sensation in the hands or feet had RP, and that primary RP represented 73% of cases of RP, and many family physicians prescribe medications for cold hands sensation based upon treatment recommendations for RP [8].

The exact prevalence of primary RP is unknown. It is a common disorder, especially in the general practice setting [9], and its prevalence is thought to be high compared with the low number of patients who seek treatment for it [10]. The treatment is mostly dependent on the etiology of the disorder and on the presence and severity of the individual symptoms. Lifestyle modifications including avoidance of cold exposure and caffeine, discontinuation of smoking, and sufficient body insulation, are the first line of treatment for the prevention of vasospasm [11,12]. If these modifications are insufficient, calcium channel blockers are the most widely used pharmacological agents for treatment [4,13,14], and in severe forms of RP, prostaglandins, endothelin-1 receptor antagonists, and specific inhibitors of phosphodiesterase-5 are the treatments of choice [6]. Although a wide variety of medications are used for treatment of RP, none have been shown to have a clear benefit, and all may be associated with unwanted side effects including headache, flushing, and dizziness. There is currently no gold standard or universal guideline for the treatment of RP [6,15].

In Korea, traditional treatments including acupuncture and herbal medications have been widely used to treat cold hands for many years, and there are a number of published reports regarding these treatments for cold hands [16-18]. Nonetheless, the present level of evidence is poor because of small sample sizes or short durations of these published studies. In addition, even though there are a few published randomized controlled trials (RCT) regarding acupuncture and RP [19,20], there is no published RCT evaluating the efficacy and safety of acupuncture in subjects with cold hands sensation. The need remains for more rigorous studies that will elucidate the efficacy and safety of acupuncture for subjects with cold hands sensation. The aim of the present study was to collect preliminary data on acupuncture compared with conventional pharmaceutical agents alone for the treatment of cold hands sensation. The results of this study will provide evidence for the feasibility of this trial design as well as basic data for a large-scale RCT of acupuncture for subjects with cold hands sensation.

Hypotheses
In this randomized controlled two-arm clinical trial, we will evaluate the acupuncture treatment as an adjunct therapy to cold hands sensation. The hypothesis is that the addition of acupuncture treatment to medication reduces the severity of cold hands sensation (measured using a visual analogue scale (VAS)) significantly more than medications alone.

Methods/Design
Design
The study is a randomized controlled pilot clinical trial. It is designed to obtain basic information of a further full-scale trial about acupuncture treatment in subjects with cold hands sensation. The protocols to be used adhere to the principles of the Declaration of Helsinki and have been approved by the Institutional Review Board of Daegu Catholic University Hospital (approval number IORG0004453), where the study will take place. The trial is registered with the Korean Clinical Research Information Service (CRIS) registry. Written informed consent will be obtained from each participant before any treatment is given.

The outcome assessments and statistical analyses will be performed by professionals blinded to the assignment of subjects. The trial process is presented in Figure 1. The trial will run for five weeks. Subjects will be randomly allocated to one of two groups, a control group, in which subjects will receive only medication for three weeks, and an experimental group, in which subjects will receive the same medication as well as nine acupuncture sessions (three sessions per week for three weeks). Assessments will be made at baseline and again at one, three, and five weeks thereafter. The five-week assessment will be performed two weeks after treatment cessation. This study will be conducted between late November 2013 to February 2014 which is winter season in South Korea. We will record room temperature to control for temperature bias in this clinical trial.

Recruitment
Participants will be recruited through advertisements on hospital websites and on bulletin boards. If subjects are interested in participating, they will be invited to the hospital for a screening meeting. Eligibility will be determined by a vascular surgeon based on the results of physical and photoplethysmography examinations. If eligible, subjects will be guided through the informed consent process. After written consent is obtained, a study researcher will randomly allocate each participant to one of the two treatment groups.
Participants
A target sample size of 14 subjects with cold hands sensation has been set. One of the main objectives of this study is to provide an estimate of the sample size required for the full-scale randomized controlled clinical trial.

Inclusion criteria
Participants must meet the following criteria for inclusion in the study: cold hands sensation or RP, photoplethysmography showing decreased arterial pulse amplitude or abnormal ischemic pulse waveform such as biphasic or monophasic wave, aged between 20 and 75 years, VAS score of >3 for cold hands sensation, symptom duration of least one month, available for follow-up during the entire trial period, and provide written informed consent.

Exclusion criteria
Participants will be excluded from the study if they meet any of the following criteria: one or more ulcerated fingers, acute ischemic disease requiring reperfusion surgery, high bleeding tendency due to anticoagulant medications, significant renal or hepatic disease, severe psychiatric or psychological disorders, known hypersensitivity reaction to acupuncture treatment, alcohol and/or drug abuse, pregnant, lactating, or planning pregnancy, any individual deemed ineligible by a physician, refusal to participate in the trial or to provide informed consent, or an inability to comprehend or express oneself in the Korean language.

Randomization
Subjects will be randomized using a computerized random number generator by an independent statistician who is blinded to subject assignment. The method which we use for randomization concealment is sequentially numbered, opaque sealed envelopes. Block randomization will be performed once a participant’s eligibility is confirmed and written informed consent has been obtained. Treatments will be scheduled after randomization.

Interventions
Subjects will be randomly divided into two treatment groups: an experimental group (acupuncture plus medication group) and a control group (medication only group). The medication will be administered every day for three weeks and the acupuncture sessions performed three times per a week for three weeks (nine times in

---

**Figure 1** Flow chart of the pilot randomized controlled trial.

Identify patients with cold hands sensation and confirm their eligibility (target number of patients = 14)

Randomize the participants

Experimental group (n = 7)
Acupuncture plus medication

Control group (n = 7)
Medication only

- Acupuncture: 3 sessions per week
- Medication:
  - nifedipine 5 mg daily
  - beraprost 20 mg three times daily

Duration of treatment: 3 weeks

Assess outcomes at baseline and at 1, 3, and 5 weeks thereafter
There are no other interventions such as moxibustion, exercises, or lifestyle advice in this study.

**Medications**

Oral nifedipine (calcium channel blocker, 5 mg once daily) and beraprost (prostaglandin analog, 20 mg three times daily) will be prescribed for all subjects in both groups.

**Acupuncture treatment**

The following acupoints will be used based on previously published work [21]: unilateral GV20, bilateral ST36, PC6, TE5, LI4, and EX-UE9 (extra points). In total, 17 acupoints will be used. Sterilized disposable acupuncture needles (DongBang Acupuncture Inc., Korea) 0.25 × 40 mm in size will be manually inserted into each of the acupoints. After needle insertion, the *deqi* sensation will be induced by manual stimulation. The needles will be inserted for 20 ± 5 minutes and then removed. Acupuncture will be practiced by Korea Medical Doctors (KMD) who are licensed by Ministry of Health and Welfare.

**Data collection**

In this study, the primary outcome will be measured by VAS. The secondary outcomes are changes in microvascular blood perfusion, frequency and duration of cold hands sensation episodes, and heart rate variability (HRV) measurements. Both primary and secondary outcomes will be assessed at baseline and at one, three, and five weeks after initiation of treatment. The treatment and outcomes measurement schedules are presented in Table 1.

**Primary outcome measurements**

**VAS** The severity of cold hands sensation episodes ranges across a continuum of values but cannot easily be measured directly. Therefore, we will use a 10-cm VAS as the measurement instrument to determine the severity of cold hands sensation. Each subject will rate each episode of cold hands sensation on a scale of 0 to 10, where 0 indicates the absence of the cold hands sensation and 10 indicates the worst cold hands sensation imaginable. VAS measurements will be made at baseline and at one, three, and five weeks thereafter.

**Secondary outcome measurements**

**Blood perfusion** Laser Doppler perfusion imaging (LDPI) with a Perimed AB LDPI system (Perimed AB, Jaerfaella, Sweden) will be used to measure the perfusion of microcirculation in the skin of the hands. The LDPI system has a moving laser beam that scans the tissue in steps and a photo detector that measures the backscattered light. The frequency shift of the light has a direct relation to the perfusion of the lighted area of skin, according to the Doppler principle [22].

The largest scanning image is 64 × 64 (4096) points and low, medium, and high resolution modes are available. The largest scanning area is about 20 × 20 cm. Measuring time is about 50 milliseconds per point, and 4 minutes for a 64 × 64 image. A normal photo is taken along with the blood perfusion scan in order to localize the area of interest. When the scan is completed, the region of interest is selected for analysis of the mean blood perfusion and its changes using the built-in LDPI windows 2.5 software.

**Frequency and duration of cold hands sensation episodes** The subjects will record the frequency and duration of each episode of cold hands sensation. The average frequency and duration of attacks will be calculated weekly by dividing the total number of attacks and their duration by the number of a given weekly interval (observation period). The frequency and duration cold hands sensation episodes will be measured at baseline and at one, three, and five weeks thereafter. We will record the frequency and duration of cold hands sensation episodes by patient diaries.

**Heart rate variation** The pathogenesis of cold hands sensation is still unclear. Neural and intravascular mechanisms are thought to be involved in the pathological progress. The role of the autonomic nervous system is most often discussed, with particular attention to sympathetic over-reactivity. HRV analysis is a reliable non-

---

**Table 1 Schedule of treatments and outcome measurements throughout the five-week randomized controlled trial**

| Measurement                  | Baseline (Week 0) | Treatment period (Week 1) | Treatment period (Week 2) | Treatment period (Week 3) | Follow-up period (Week 4) | Follow-up period (Week 5) |
|------------------------------|------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| VAS                          | √                | √                        | √                        | √                        | √                        | √                        |
| Blood perfusion              | √                | √                        | √                        | √                        | √                        | √                        |
| Frequency and duration of cold hands episodes | √ | √ | √ | √ | √ | √ |
| HRV                          | √                | √                        | √                        | √                        | √                        | √                        |
| Medication                   | √                | √                        | √                        | √                        | √                        | √                        |
| Acupuncture                  | √                | √                        | √                        | √                        | √                        | √                        |

HRV: Heart rate variability, VAS: visual analogue scale.
HRV will be measured using a Medicore SA-2000E analyzer (Medicore Co., Ltd., Seoul, South Korea) with four limb electrodes. To minimize the influence of confounding factors, all subjects were prohibited from using drugs, caffeine, tobacco, and alcohol for eight hours before HRV testing. The frequency domain methods of HRV analysis will be used. Low frequency (LF), high frequency (HF), LF:HF ratio, LF in normalized units, and HF in normalized units will be measured. LF reflects the sympathetic influence, whereas HF reflects the parasympathetic influence. The LF:HF ratio reflects the interaction between sympathetic and vagal activity. LF in normalized units and HF in normalized units are the respective values of LF and HF divided by the sum of LF plus HF and multiplied by 100; thus, the sum of LF in normalized units and HF in normalized units is 100 [24]. HRV measurements will be conducted at baseline and at one, three, and five weeks thereafter.

**Safety**

The safety of this trial will be determined by red blood cell (RBC) count, hemoglobin level, platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) level, mean corpuscular hemoglobin concentration (MCHC), hematocrit (Hct), total white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine level, serum sodium level, serum potassium level, and serum chloride level. All subjects are evaluated twice, first at the screening visit and once more after the termination of acupuncture treatments. To monitor the safety of the acupuncture treatment, we will monitor the occurrence of edema, hemorrhage, and pain as adverse events.

Any reported adverse events will be recorded throughout the study and vital signs will be monitored at each visit. The subjects will be asked to voluntarily report information about adverse events, and the researcher will confirm the occurrence of adverse events through methods such as a medical interview. Details about adverse events, such as the date of occurrence, degree of severity, causal relationship with the treatment, other treatments or medications that are suspected to cause the adverse event, and treatment of the adverse event will be recorded in detail.

**Withdrawal and dropout**

All subjects will have the right to withdraw from the study at any time. Participation will be ended at any stage if the subject refuses to continue, withdraws consent, or violates the inclusion or exclusion criteria or the trial protocol. The trial will be stopped if the principal investigator believes that there are unacceptable risks of serious adverse events.

**Statistical analysis**

The statistical significance level will be set at 5%, and the data will be processed with the last observation carried forward method for the intention-to-treat analysis. Statistical analysis in this study will be performed using IBM SPSS Windows version 19.0 statistical software (IBM Co., Armonk, NY, USA) and will be based on the Korean Clinical Trial Statistics Guidelines.

The study will identify the comparative equivalence of demographic variables and clinical characteristics between the experimental and control groups by performing the two sample t-test or Mann-Whitney U test if normality test is satisfied or not for continuous data, chi-square test for categorical data.

A repeated measure two-factor analysis will be performed to identify differences in VAS, blood perfusion, frequency and duration of cold hands sensation attacks and HRV scores between the experimental and control group based on time (baseline, weeks one, three, and five). If the interaction between group and time is statistically significant, the point at which the pattern of results between the two groups changes will be checked using the contrast analysis. To compare groups and the incidence frequency of adverse events related to acupuncture and medication, the chi-square test will be used.

**Discussion**

Cold hands sensation is a common disorder within the Korean population. In Korea, many physicians believe the phenomenon is related to RP, and they may prescribe pharmaceutical treatments similar to those used for patients with RP [5,8]. However, there is no established guideline for RP therapy, and many of the agents most frequently used in the treatment of RP are used off-label [15] and consist mainly of vasodilators, in particular calcium channel antagonists such as nifedipine. While these agents have proven useful in some reports [14], in about 50% of patients, there is no beneficial effect [15]. Furthermore, their use has often been associated with an unacceptably high incidence of side effects including edema, flushing, erythema, dizziness, nausea, palpitations, and drowsiness [25,26]. Beraprost is the first oral prostaglandin analog with vasodilatory and antiplatelet effects which has been used in the treatment of RP. To date, one double blind study has indicated that there was no difference between oral beraprost and placebo in the treatment of primary RP, and the same study found that patients in the beraprost group reported a significantly higher incidence of side effects including
headache; dose increase was also limited by side effects such as headache, flushing, and diarrhea [15,27]. The high prevalence of RP in the general population and the unfavorable side effects profiles of the present medications further demonstrate the need for alternative treatment options.

Acupuncture is one of the most important components of complementary and alternative medicine. It is a therapy that has been used for thousands of years in Korea. Recently, there has been increased interest in the therapeutic benefits of acupuncture [28]. In South Korea, many subjects with cold hands sensation already choose traditional Korean medicines such as acupuncture for treatment. However, thus far, there are no published controlled clinical trials investigating the efficacy and safety of acupuncture for treatment of cold hands sensation. We have therefore designed this pilot RCT to guide the design of a full-scale trial. Our study will be a first randomized controlled trial regarding cold hands sensation, but it has limitation of small sample size. We expect this pilot study to provide a clinical foundation for a future large-scale trial as well as information about the feasibility of such a trial.

**Trial status**

This trial’s recruitment was finished.

**Abbreviations**

HF: High frequency; HRV: Heart rate variability; LDPI: Laser doppler perfusion imaging; LF: Low frequency; RP: Raynaud’s phenomenon; VAS: Visual analogue scale.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

JCS and HJL designed the study. MAK and SHP conducted the study. JCS and HJL designed the study. IHS contributed to the design of the data handling. WSY and KHP had primary responsibility for the final content of the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

This study was supported by a grant from the Ministry of Health & Welfare, Republic of Korea, 2013.

**Author details**

1. Comprehensive and Integrative Medicine Institute, 3056-6 Daemyeong 4-dong, Nam-gu, Daegu 705-718, Republic of Korea. 2. Department of Acupuncture & Moxibustion, College of Oriental Medicine, Daegu Haany University, 165 Sang-dong, Suseong-gu, Daegu 706-060, Republic of Korea. 3. Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University, 165 Sang-dong, Suseong-gu, Daegu 706-060, Republic of Korea. 4. Division of Vascular Surgery, Department of Surgery, School of Medicine, Catholic University of Daegu, 3056-6 Daemyeong 4-dong, Nam-gu, Daegu 705-718, Republic of Korea. 5. Department of Medical Statistics, School of Medicine, Catholic University of Daegu, 3056-6 Daemyeong 4-dong, Nam-gu, Daegu 705-718, Republic of Korea. 6. School of Medicine, Catholic University of Daegu, 3056-6 Daemyeong 4-dong, Nam-gu, Daegu 705-718, Republic of Korea.

Received: 20 January 2014 Accepted: 6 August 2014 Published: 4 September 2014

**References**

1. Hur YM, Chae JH, Chung KW, Kim JJ, Jeong HU, Kim JW, Seo SY, Kim KS: Feeling of cold hands and feet is a highly heritable phenotype. Twin Res Hum Genet 2012, 15:166–169.
2. The Asan Medical Center. [http://www.amc.seoul.kr/asan/healthinfo/disease/DiseaseDetail.do?contentNo=32098].
3. Maricq HR, Weinrich MC, Kel JE, Smith EA, Harper FE, Nussbaum AJ, LeRoy EC, McGregor AR, Diat F, Rosal EJ: Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989, 32:998–1006.
4. Wagley FA: Clinical practice: Raynaud’s phenomenon. N Engl J Med 2002, 347:1001–1008.
5. Kim CM, Ock SM, Chung JH, Jang HS, Yoo DJ, Lee JB, Choi WS: Recognition of family practitioners on cold hands/feet syndrome and Raynaud’s disease. Korean J Fam Med 2007, 28:339–345.
6. Lambova SN, Muller-Ladner U: New lines in therapy of Raynaud’s phenomenon. Rheumatol Int 2009, 29:355–363.
7. Choi WS, Ock SM, Byeon JH, Jung SH, Park KS, Park JW, Yoo DJ, Lee JB, Kim CM: The prevalence of diagnosis as Raynaud’s disease among the people complaint of abnormal sensation on hands and feet. J Korean Acad Fam Med 2003, 24:1085–1091.
8. Kim CM: The diagnosis and treatment of cold hands/feet syndrome. J Korean Acad Fam Med 2004, Suppl 11:273–277.
9. Choi WS, Choi CJ, Kim KS, Lee JH, Song CH, Chung JH, Ock SM, Lee JB, Kim CM: To compare the efficacy and safety of nifedipine sustained release with Gingko biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study). Clin Rheumatol 2009, 28:553–559.
10. Silman A, Holligan S, Brennan P, Maddison P: Prevalence of symptoms of Raynaud’s phenomenon in general practice. BMJ 1990, 301:590–592.
11. Bakrit R, Menola JF, Franks AG Jr, Sanchez M: Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol 2008, 59:633–653.
12. Herrick AL: Treatment of Raynaud’s phenomenon: new insights and developments. Curr Rheumatol Rep 2003, 5:168–174.
13. Porter JM, Rivers SP, Anderson CJ, Baur GM: Evaluation and management of patients with Raynaud’s syndrome. Ann J Surg 1981, 142:183–189.
14. Thompson AE, Pope JE: Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford) 2005, 44:145–150.
15. Levien TL: Advances in the treatment of Raynaud’s phenomenon. Vasc Health Risk Manag 2010, 6:167–177.
16. Shin KR, Kwak SA, Lee JB, Yi HR: The effectiveness of hand acupuncture and moxibustion in decreasing pain and “coldness” in Korean women who have had hysterectomy: a pilot study. Appl Nurs Res 2006, 19:22–30.
17. Ryoo GS, Lee JM, Lee CH, Cho JH, Jang JB, Lee KS: A case report of cold hypersensitivity caused by acute and chronic blood deficiency. J Orient Obstet Gynecol 2009, 22:223–230.
18. Lee YJ, Hwang DS, Cho JH, Lee CH, Jang JB, Kim YS, Lee KS: Effects of acupuncture on patients with cold hypersensitivity by cold stress test pilot study. J Orient Med Thermol 2006, 5:69–77.
19. Hahn M, Steins A, Möhle M, Blum A, Jünger M: Is there a vasospasmolytic effect of acupuncture in patients with secondary Raynaud phenomenon? J Dtsch Dermatol Ges 2004, 2:759–762.
20. Appiah R, Hiller S, Caspar L, Alexander K, Creutzig A: Treatment of primary Raynaud’s syndrome with traditional Chinese acupuncture. J Intern Med 1997, 241:119–124.
21. The textbook compilation committee of Korean acupuncture and moxibustion medicine society. Textbook of the Acupuncture and Moxibustion Medicine. Paju: Apsamoonang; 2012:849.
22. Litcher G: Bioengineering assessment of acupuncture, part 2: monitoring of microcirculation. Crit Rev Biomed Eng 2006, 34:273–294.
23. Xhyheri B, Manfrini O, Mazzolini M, Pizzi C, Bugiardini R: Heart rate variability today. Prog Cardiovasc Dis 2012, 55:321–331.
24. Task Force of the European Society of Cardiology and the North American Society of Pacing Electrophysiology: Heart rate variability: standards of measurement, physiological interpretation and clinical use: task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996, 93:1043–1065.
25. Raynaud’s Treatment Study Investigators: Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow up. Arch Intern Med 2000, 160:101–1108.
26. Corbin DO, Wood DA, Macintyre CC, Housley E: A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud’s phenomenon. Eur Heart J 1986, 7:165–170.

27. Vayssairat M: Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud’s phenomenon: French Microcirculation Society Multicentre Group for the Study of Vascular Acrsyndromes. J Rheumatol 1996, 23:1917–1920.

28. Frass M, Strassl RP, Friehs H, Mullner M, Kundi M, Kaye AD: Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review. Ochsner J 2012, 12:45–56.

doi:10.1186/1745-6215-15-348

Cite this article as: Seo et al.: Acupuncture in subjects with cold hands sensation: study protocol for a randomized controlled trial. Trials 2014 15:348.